Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $95.9 million.

  • Nurix Therapeutics' Total Current Liabilities fell 4.57% to $82.3 million in Q3 2025 from the same period last year, while for Aug 2025 it was $82.3 million, marking a year-over-year decrease of 4.57%. This contributed to the annual value of $95.9 million for FY2024, which is 10.23% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Total Current Liabilities of $95.9 million as of FY2024, which was up 10.23% from $87.0 million recorded in FY2023.
  • Nurix Therapeutics' Total Current Liabilities' 5-year high stood at $95.9 million during FY2024, with a 5-year trough of $44.5 million in FY2020.
  • Moreover, its 3-year median value for Total Current Liabilities was $87.0 million (2023), whereas its average is $84.5 million.
  • Data for Nurix Therapeutics' Total Current Liabilities shows a peak YoY skyrocketed of 176.01% (in 2020) over the last 5 years.
  • Over the past 5 years, Nurix Therapeutics' Total Current Liabilities (Yearly) stood at $44.5 million in 2020, then spiked by 48.76% to $66.3 million in 2021, then rose by 6.64% to $70.7 million in 2022, then climbed by 23.07% to $87.0 million in 2023, then increased by 10.23% to $95.9 million in 2024.